Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.
2 X 4-1BB bispecific) Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific) Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024 , and cash runway expected into 2027 I-Mab will hold a conference call and webcast today, August 28 th , at 8:00 AM ET ROCKVILLE, Md. , Aug.
28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent pipeline progress and business updates.
"I-Mab is delivering on its strategic plan, as demonstrated by our corporate development and pipeline progress in 2024, said Sean Fu , PhD, interim CEO and Board Member of I-Mab. "I am very pleased to report that we are executing on our Board's vision by establishing a new operating model as a U.S.
-based global biotech company and completing the divestiture of our operations in China , streamlining the organization, transitioning to U.S.-based .